ID   CBL-1
AC   CVCL_K136
SY   CBL1
DR   CLO; CLO_0002213
DR   ABCD; ABCD_AR015
DR   ATCC; HB-8214
DR   Wikidata; Q54808674
RX   Patent=US5330896;
RX   Patent=US20070048305;
RX   PubMed=6208131;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8214.
CC   Biotechnology: Was used to produce the monoclonal antibody gavilimomab (ABX-CBL) which was intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease (Patent=US20070048305).
CC   Monoclonal antibody isotype: IgM.
CC   Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 11-02-13; Last updated: 02-05-24; Version: 7
//
RX   Patent=US5330896;
RA   Billing R.J.;
RT   "Monoclonal antibodies to an autocrine growth factor antigen that
RT   binds to activated lymphocytes and cancer cells.";
RL   Patent number US5330896, 19-Jul-1994.
//
RX   Patent=US20070048305;
RA   Davis C.G., Blacher R.W., Corvalan J.R., Culwell A.R., Green L.L.,
RA   Hales J., Havrilla N., Ivanov V.E., Lipani J.A., Liu Q., Weber R.F.,
RA   Yang X.-D.;
RT   "CD147 binding molecules as therapeutics.";
RL   Patent number US20070048305, 01-Mar-2007.
//
RX   PubMed=6208131; DOI=10.1089/hyb.1.1982.1.303;
RA   Billing R.J., Wells J., Zettel D., Terasaki P.I.;
RT   "Monoclonal and heteroantibody reacting with different antigens common
RT   to human blast cells and monocytes.";
RL   Hybridoma 1:303-311(1982).
//